The kinetics of mobilization and optimal timing of peripheral blood progenitor cell (PBPC) collection were evaluated in 190 patients with multiple myeloma undergoing stem cell harvest after mobilization with cyclophosphamide, prednisone and G-CSF. There was a strong correlation between the WBC count and the number of CD34 ؉ cells circulating in peripheral blood (r ‫؍‬ 0.875). Initiating leukapheresis based on rising WBC and platelet counts rather than on a fixed day increased the mean number of CD34 ؉ cells 115% (9.7 to 20.9 ؋ 10 6 CD34 ؉ cells/kg; P ‫؍‬ 0.010) for the total of all leukaphereses and 59% for the total of all CD34-selected products (5.1 to 8.1 ؋ 10 6 CD34 ؉ cells/kg; P ‫؍‬ 0.011). Although the yield and purity of the CD34-selected product were not significantly affected (P у 0.071), the percentage of patients with concentrations of CD34 ؉ cells in the initial leukapheresis of Ͼ1% increased from 47% to 70% (P ‫؍‬ 0.004). The mean purity of the selected product was related to the starting percentage: 48.9% if Ͻ1% and 81.5% if у1% (P Ͻ 0.001). Collection of stem cells based on rising WBC and platelet counts significantly increased the number of CD34 ؉ cells in leukaphereses and CD34-selected products in comparison with collection on a fixed day.
Summary:
The kinetics of mobilization and optimal timing of peripheral blood progenitor cell (PBPC) collection were evaluated in 190 patients with multiple myeloma undergoing stem cell harvest after mobilization with cyclophosphamide, prednisone and G-CSF. There was a strong correlation between the WBC count and the number of CD34 ؉ cells circulating in peripheral blood (r ‫؍‬ 0.875). Initiating leukapheresis based on rising WBC and platelet counts rather than on a fixed day increased the mean number of CD34 ؉ cells 115% (9.7 to 20.9 ؋ 10 6 CD34 ؉ cells/kg; P ‫؍‬ 0.010) for the total of all leukaphereses and 59% for the total of all CD34-selected products (5.1 to 8.1 ؋ 10 6 CD34 ؉ cells/kg; P ‫؍‬ 0.011). Although the yield and purity of the CD34-selected product were not significantly affected (P у 0.071), the percentage of patients with concentrations of CD34
؉ cells in the initial leukapheresis of Ͼ1% increased from 47% to 70% (P ‫؍‬ 0.004). The mean purity of the selected product was related to the starting percentage: 48.9% if Ͻ1% and 81.5% if у1% (P Ͻ 0.001). Collection of stem cells based on rising WBC and platelet counts significantly increased the number of CD34 ؉ cells in leukaphereses and CD34-selected products in comparison with collection on a fixed day. Keywords: CD34 ϩ cell; PBSC; CD34 selection; CEPR-ATE SC Peripheral blood progenitor cells (PBPC) have been increasingly substituted for bone marrow in autologous transplantations because of the ease of collection and the shorter time to engraftment. Although the number of PBPC is relatively low in the steady-state circulation, the numbers increase significantly after administration of cytotoxic drugs, hematopoietic growth factors or a combination of both. of chemotherapy and growth factors have been reported to optimize mobilization of CD34 ϩ cells. [3] [4] [5] [6] Factors that affect the CD34 ϩ cells in the PBPC product collected include the status of the patient's disease, prior treatment with chemotherapy and radiation, 7 as well as the regimen used to mobilize the stem cells. 4, 6 In addition to optimizing the regimen used to mobilize the patients, the number of progenitor cells collected can be maximized by appropriate timing of the collection of PBPC. Centers collecting PBPC have attempted to predict the optimal time to collect by measuring the white blood cell count (WBC) 8, 9 or the number of CD34 ϩ cells in the peripheral blood. [10] [11] [12] We conducted an open label, multi-center, randomized, controlled phase III study that evaluated autologous transplantation with unselected PBPC vs CD34-selected PBPC obtained using the CEPRATE SC Stem Cell Concentration System (CEPRATE SC System; CellPro, Bothell, WA, USA). Patients were mobilized with cyclophosphamide, prednisone and G-CSF. Based on the successful results of a phase II study, patients initially underwent leukapheresis beginning on day 15. 13 Preliminary data from the analysis of daily counts suggested that collection on day 15 missed the peak of circulating CD34 ϩ cells. Consequently, the first day of leukapheresis was changed to a flexible day determined by a rising WBC and platelet count. Leukaphereses from the first 58 patients were collected on a fixed day (day 15) and from the next 132 patients based on a rising WBC and platelet count.
This study was a retrospective analysis of the kinetics of mobilization of stem cells in the peripheral blood and the effect of a fixed vs a flexible day for initiating leukapheresis on unselected and CD34-selected products.
Materials and methods

Study population
One hundred and ninety patients with advanced multiple myeloma and responsive or stable disease after 3 to 6 months of cytotoxic therapy were mobilized and had PBPC collected on a phase III, open-label study conducted at 15 sites in the United States and Canada. The median age of the patients was 52 with a range of 33 to 70 years. The median time from diagnosis to randomization was 6 months and the median number of prior cycles of chemotherapy was four (range 2-9). Ninety-three of the patients were randomized to the CD34-selected arm and 97 were randomized to the unselected arm.
Mobilization and collection of PBPC
All patients received cyclophosphamide (2.5 g/m 2 ) intravenously on the first day of mobilization, prednisone (2 mg/kg/day) orally for the first 4 days of mobilization and G-CSF (10 g/kg/day) subcutaneously beginning on the second day of mobilization and continuing until the last day of leukapheresis.
For the first 58 patients, leukapheresis was initiated on day 15 of mobilization (fixed day) unless these criteria were not met. For the 132 subsequent patients, leukapheresis was initiated when the patient met both of the preceding criteria on two occasions greater than 24 h apart (flexible day).
PBPC were collected using standardized leukapheresis procedures. Leukapheresis was performed daily for a minimum of 2 days and continued until 5 ϫ 10 8 nucleated cells/kg was obtained. This procedure was used in an attempt to achieve a cell dose of at least 2.0 ϫ 10 6 CD34 ϩ cells/kg that was established in the previous phase II study as a threshold to increase the likelihood of rapid engraftment. 13 The day of first leukapheresis, the number of leukaphereses, and the number of nucleated cells and CD34 ϩ cells in each leukapheresis and in the infused product were determined for all patients. Additionally, a WBC count with differential, a platelet count, and the number of CD34 ϩ cells in the peripheral blood were obtained for 37 patients enrolled at six of the sites for day 1 and days 8 to 14 of mobilization.
Samples were analyzed by Cytometry Associates (Brentwood, TN, USA) using fluorochrome-conjugated monoclonal antibodies and a flow cytometer. Briefly, samples from the leukapheresis product, CD34-selected product and the CD34-depleted product were incubated with anti-CD14 monoclonal antibody conjugated with fluorescein isothiocyanate (CD14-FITC), and with either anti-CD34 monoclonal antibody (CD34-PE) or an isotypic control (MsIgG-PE) conjugated with phycoerythrin. In addition, the cells were stained with 7-Actinomycin D (7-AAD) to assess viability. After acquisition of data from the flow cytometer, the CD34 cells were identified based on Boolean gating of light scatter, viability and absence of CD14 expression. The percent CD34 ϩ positive cells was calculated by dividing the number of CD34-positive events, derived from the above gating strategy, by the total nucleated cells acquired, and multiplying this result by 100.
Statistical methods
In order to evaluate the numbers of CD34 ϩ cells and WBCs during mobilization results were analyzed from those patients with data for at least 6 days during mobilization (n ϭ 14). The correlation (Pearson correlation) of WBC with number of CD34 ϩ cells was calculated using all data from the 14 patients in the subgroup.
In order to evaluate the effect that timing of the first leukapheresis had on the collection of PBPC, the results of comparisons between patients for whom leukapheresis was initiated on a fixed day vs a flexible day were performed using a two-sample t-test or Wilcoxon rank sum test, as appropriate. Analyses were performed on the leukapheresis products for all 190 patients. Additional analyses were performed for 93 patients whose PBPC product was CD34 selected.
Results
CD34 ϩ cells, WBC and platelets in the peripheral blood during mobilization
There was a strong correlation between the WBC count and the number of CD34 ϩ cells for the 14 patients with data for at least 6 days (P ϭ 0.875).
There was no correlation between platelet count and the number of CD34 ϩ cells circulating in the peripheral blood.
Effect of a fixed vs a flexible day for initiating leukapheresis on the leukapheresis products for the total patient population
The median number of days from the start of mobilization to the first leukapheresis decreased from 15 days for patients with a fixed date of collection to 12 days for patients in which the first day of collection was based on the WBC and platelet count (P Ͻ 0.001).
Initiating leukaphereses based on a rising WBC and platelet count had a significant effect on the number of leukaphereses required to reach a threshold of 2.0 ϫ 10 6 CD34 ϩ cells/kg (P ϭ 0.013). Furthermore, the percentage of patients who reached the threshold in one or two leukaphereses was increased (76-90%; P ϭ 0.023) and the percentage who never reached the goal was decreased (14-5%; see Figure 1 , P ϭ 0.039). Initiating leukapheresis on a flexible day based on a rising WBC and platelet count had no effect on the number of nucleated cells per kilogram collected in the first leukaphereses or on the cellular yield after all leukaphereses (P у 0.119). However, there was an increase in the number of CD34 ϩ cells in the individual leukapheresis products and the total for all leukapheresis products. The mean numbers of CD34 ϩ cells/kg were 110% and 105% higher for the first (5.1 vs 10.7 ϫ 10 6 CD34 ϩ cells/kg) and second leukapheresis (4.3 vs 8.8 ϫ 10 6 CD34 ϩ cells/kg), respectively ( Figure 2) . Overall, the mean number of CD34 ϩ cells increased 115% (9.7 to 20.9 ϫ 10 6 CD34 ϩ cells/kg) for the total of all leukaphereses. The median number of CD34 ber of CD34 ϩ cells collected. The concentration significantly increased in the PBPC product of patients whose leukaphereses were initiated based on a rising WBC and platelet count. The mean percentage of CD34 ϩ cells increased from 1.32% to 2.97% (median 0.9-2.0) for the first leukapheresis and from 1.12% to 2.41% for the second leukapheresis (median 0.8-1.5; P Ͻ 0.010) when the CD34 ϩ cells were collected on a fixed day vs a flexible day.
Effect of the change in criteria to begin PBPC collection on processing of CD34 ϩ cells with the CEPRATE SC Stem Cell Concentration System
There was no significant difference in the number of leukaphereses required to reach the threshold dose of 2.0 ϫ 10 6 CD34 ϩ cells/kg in the CD34-selected product when leukapheresis was initiated on a fixed day (day 15) vs a flexible day based on the rising WBC and platelet count + cells/kg in the CD34-selected product for patients who had less than or equal to 1% CD34 cells in the first leukapheresis compared to those with more than 1% CD34 + cells.
(P ϭ 0.093). However, the mean number of CD34 ϩ cells per kilogram for the selected product in all leukaphereses was 59% higher for patients with a flexible rather than a fixed collection day (5.1 ϫ 10 6 vs 8.1 ϫ 10 6 , median 4.1 ϫ 10 6 vs 6.2 ϫ 10 6
; P ϭ 0.055). The yield and the purity of the CD34-selected product were not significantly affected by the change in day of collection (P у 0.071).
Although there was no significant effect in the purity of the selected product, there was a relationship between the percentage of the CD34 ϩ cells in the initial leukapheresis and the percentage in the selected product. If the percentage of CD34 ϩ cells in the start was less than 1%, the mean purity (± s.e.m.) of the selected fraction was 48.9 ± 4.4 (median 53.9). When the percentage in the start was greater than or equal to 1%, the mean purity (± s.e.m.) of the selected product was 81.5 ± 1.7 (median 85.2; P р 0.001). Changing the day of collection to a flexible day increased the percentage of patients with a CD34 ϩ concentration in the initial leukapheresis of greater than 1% from 47% to 70% (P ϭ 0.005). Furthermore, the number of leukaphereses required to reach 2.0 ϫ 10 6 CD34 ϩ cells/kg was significantly less when the concentration of CD34 ϩ cells was greater than 1% in the initial leukapheresis (see Figure 3 , P Ͻ 0.001).
Discussion
Initiating leukaphereses after the nadir and when the patient had a rising WBC and platelet count for at least 24 h increased the mean and median number of CD34 ϩ cells collected by approximately 100% when compared to initiating the leukapheresis 15 days after the initiation of mobilization chemotherapy. This increase in the number of CD34 12 who also found that optimizing the timing of the leukapheresis resulted in an increase in the percentage of patients who reached 2.0 ϫ 10 6 CD34 ϩ cells in less than three leukaphereses.
The yield and the purity of the CD34-selected product were not significantly changed when leukapheresis was initiated based on a rising WBC and platelet count. However, the percentage of patients with a concentration in the leukapheresis of greater than 1% increased from 47% to 70%. Starting concentrations of greater than 1% generally resulted in a CD34-selected product with purity greater than 60%. This result is consistent with the observations of Watts et al. 14 In addition, the number of leukaphereses required to reach 2.0 ϫ 10 6 CD34 ϩ cells/kg in the CD34-selected product was less if the concentration was greater than 1%. Taken together, these data suggest that the purity of the product is likely to be higher and the number of leukaphereses fewer if the day on which collection begins is optimized.
Transplant groups use a variety of measures to guide the timing of the PBPC collection for stem cells. Our results agree with three other reports that a rising blood leukocyte count can be used successfully as a guide to harvest stem cells. [15] [16] [17] In the first two studies, peak levels of CD34 ϩ cells were observed 2 to 4 days after the nadir of the WBC. In the third study, a WBC greater than 800/l at the initiation of the leukapheresis provided a better cell yield. Enumeration of CD34 ϩ cells in the peripheral blood is also effectively used in some centers to determine the optimal time for initiation of leukaphereses for collection of stem cells. 10, 12 Some investigators argue that counting CD34 ϩ cells has the advantage of predicting whether or not mobilization is adequate in an individual patient. 7, 12 The disadvantage is that some centers do not have a flow cytometer or results may not be available for several hours after the patient sample is drawn. Collection of stem cells based on the rising WBC and platelet count has the advantage of being simple, inexpensive and readily available. Our results demonstrate that collection of stem cells based on the rising WBC and platelet count significantly increased the number of CD34 ϩ cells in the leukapheresis product in comparison with a fixed day of collection.
